Cholinesterase inhibitor use in amyloid PET-negative mild cognitive impairment and cognitive changes
The association between ChEI use and accelerated cognitive decline may stem from underlying pathologies involving reduced hippocampal volume, entorhinal cortical thickness and faster frontal lobe atrophy. We suggest that ChEI use in amyloid PET-negative MCI patients might need further consideration, and studies investigating the causality between ChEI use and cognitive decline are warranted in the future.
Authors
- SangYun Kim (ORCID: https://orcid.org/0000-0002-9101-5704)
- Min Ju Kang (ORCID: https://orcid.org/0000-0002-7736-6073)
- Jung‐Min Pyun (ORCID: https://orcid.org/0000-0002-8391-5729)
- Young Ho Park (ORCID: https://orcid.org/0000-0002-2756-1786)
Institutions
- Soonchunhyang University Hospital Seoul (KR)
- Seoul National University Bundang Hospital (KR)
- Veterans Health Service Medical Center (KR)
Publication Details
- Journal
- Alzheimer s Research & Therapy
- Published
- 2024-10-02
- DOI
- https://doi.org/10.1186/s13195-024-01580-y
- Citations
- 3
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- Pfizer
- University of Southern California
- Alzheimer's Disease Neuroimaging Initiative
- Novartis Pharmaceuticals Corporation
- Northern California Institute for Research and Education
- Soonchunhyang University
- Servier
- National Institutes of Health
- Canadian Institutes of Health Research